Unione Europea - italiano - EMA (European Medicines Agency)

ucb pharma s.a. - romosozumab - osteoporosi - farmaci per il trattamento delle malattie ossee - evenity è indicato nel trattamento della grave osteoporosi nelle donne in postmenopausa ad alto rischio di frattura.

Unione Europea - italiano - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasi - immunosoppressori - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - emicrania - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - agenti antineoplastici - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

galderma international - tartrato di brimonidina - malattie della pelle - altri preparati dermatologici - mirvaso è indicato per il trattamento sintomatico dell'eritema facciale della rosacea nei pazienti adulti.